Puma Biotechnology

ALISCA™-Lung1 Active Sites

Puma anticipates opening the ALISCA™-Lung1 trial at approximately 25 study sites within the United States by the end of 2024. Below is a list of study sites currently open to enrollment as of 31/JUL/2024. Please note study site availability for enrollment is subject to change without notice. Please contact Puma at clinicaltrials@pumabiotechnology.com should you have any questions regarding open sites.

Center Name

City

State

Phone

Southern Cancer Center, PC	Daphne	AL	(251) 625-6896
The Oncology Institute of Hope and Innovation	Long Beach	CA	(562) 232-0550
Rocky Mountain Cancer Centers, LLP	Lone tree	CO	(303) 925-0700
Georgetown University, Lombardi Comprehensive Cancer Center	Washington	DC	(202) 444-2223
The Oncology Institute of Hope and Innovation	Ft. Lauderdale	FL	(754) 336-3426
Illinois Cancer Specialists	Niles	IL	(847) 827-9060
Henry Ford Hospital	Detroit	MI	(313) 916-2600
Minnesota Oncology Hematology, P.A.	Burnsville	MN	(952) 892-7190
Cleveland Clinic Taussig Cancer Center	Cleveland	OH	(216) 445-9282
University Hospitals Cleveland Medical Center - Seidman Cancer Center	Cleveland	OH	(216) 844-1228
Oncology Hematology Care Clinical Trials, LLC	Cincinnati	OH	(513) 751-2273
Sarah Cannon Zangmeister Cancer Center - Columbus	Columbus	OH	(614) 383-6000
Oncology Associates of Oregon P.C.	Eugene	OR	(541) 683-5001
UPMC Hillman Cancer Center	Pittsburgh	PA	(412) 692-4724
Sarah Cannon Tennessee Oncology - Nashville	Nashville	TN	(615) 329-7640
University of Texas Southwestern Medical Center	Dallas	TX	(214) 645-4673
University of Virginia Health System	Charlottesville	VA	(434) 924-9333
Virginia Cancer Specialists (VCS) Research Institute	Fairfax	VA	(571) 350-8400
Oncology & Hematology Associates of Southwest Virginia, Inc.	Blacksburg	VA	(540) 381-5291
Northwest Cancer Specialists, P.C.	Vancouver	WA	(360) 944-9889
Marshfield Clinic Health System	Rapids	WI	(715) 393-1400